We are a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Our lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept is currently in multiple Phase 1 and 2 clinical trials. We are currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Our strategy is to pursue evorpacept as a potentially critical component of future oncology combination treatments.

Leadership Team

Jason Lettmann

Chief Executive Officer

Jaume Pons, PhD

President and Chief Scientific Officer

Sophia Randolph, MD, PhD

Chief Medical Officer

Chris Byrd, JD, PhD

General Counsel

Allison Dillon, PhD

Chief Business Officer

Peter García

Chief Financial Officer

Shelly Pinto

Senior Vice President Finance and Chief Accounting Officer

Management Team

Yeong-Liang Lin, MD, MS

Senior Vice President, Drug Safety and Pharmacovigilance

Sue Naim

Senior Vice President, Clinical Operations

Lisa Sauer

Senior Vice President, Regulatory Affairs and Quality Assurance

Athanasios Tsiatis, MD

Senior Vice President, Clinical Development

Michael Chang, PhD

Vice President, Operations

Venita De Almeida, PhD

Vice President, Head of Research Program Development

Hadi Falahatpisheh, DVM, PhD, DABT

Vice President, Preclinical Development

Shanhong Guan, PhD

Vice President, Biometrics

Hank Stern

Vice President, Chemistry, Manufacturing and Controls

Marija Vrljic, PhD

Vice President, Antibody Technologies